| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Bellerophon Therapeutics, Inc. | Chief Executive Officer, Principal Financial and Accounting Officer | Stock Options (Right to Buy) | 100K | $152K | $1.52 | Jun 7, 2023 | Direct |
| Bellerophon Therapeutics, Inc. | Chief Executive Officer, Principal Financial and Accounting Officer | Common Stock | 22.5K | $2.34K | $0.10 | Dec 9, 2022 | Direct |
| Bellerophon Therapeutics, Inc. | Chief Executive Officer, Principal Financial and Accounting Officer | Restricted Stock Units | 32.5K | Dec 9, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| BLPH | Bellerophon Therapeutics, Inc. | Jun 7, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Chief Executive Officer, Principal Financial and Accounting Officer |
| BLPH | Bellerophon Therapeutics, Inc. | Feb 10, 2023 | 1 | $152K | 4 | Feb 14, 2023 | CHIEF EXECUTIVE OFFICER |
| BLPH | Bellerophon Therapeutics, Inc. | Dec 9, 2022 | 3 | -$9.29K | 4 | Dec 13, 2022 | PRINCIPAL EXECUTIVE OFFICER |
| BLPH | Bellerophon Therapeutics, Inc. | Jan 26, 2022 | 1 | $0 | 4 | Jan 28, 2022 | CHIEF REGULATORY & SAFETY OFFR |